Trial
NCT02663518
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Pfizer
Collaborators
—
Condition
Hematologic Malignancies
Intervention
PF-0791800 (TTI-621)
Why stopped
Pfizer decided terminating study for administrative reasons on 22Mar2022 (stopping enrollment as of 15Apr2022). The decision wasn't due to safety concerns or requests from regulatory authorities.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-10